clomipramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
substances of the imipramine group	701	303-49-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clomipramine chlorimipramine clomipramine hydrochloride clomipramine HCl	A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. Molecular weight: 314.86 Formula: C19H23ClN2 CLOGP: 5.92 LIPINSKI: 1 HAC: 2 HDO: 0 TPSA: 6.48 ALOGS: -4.34 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clomipramine
chlorimipramine
clomipramine hydrochloride
clomipramine HCl

A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.

Molecular weight: 314.86
Formula: C19H23ClN2
CLOGP: 5.92
LIPINSKI: 1
HAC: 2
HDO: 0
TPSA: 6.48
ALOGS: -4.34
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
0.10	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	13.24 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	51 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	13 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.03 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	26 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 29, 1989	FDA	MALLINCKRODT LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	242.73	16.29	148	11172	64216	63413486
Intentional overdose	230.82	16.29	151	11169	74001	63403701
Serotonin syndrome	176.42	16.29	91	11229	28591	63449111
Drug interaction	150.12	16.29	194	11126	228937	63248765
Poisoning deliberate	142.82	16.29	59	11261	11159	63466543
Overdose	142.33	16.29	136	11184	114942	63362760
Suicide attempt	133.21	16.29	100	11220	60818	63416884
Bezoar	120.87	16.29	32	11288	1494	63476208
Intentional self-injury	104.26	16.29	62	11258	25625	63452077
Toxicity to various agents	100.18	16.29	167	11153	247083	63230619
Depressed level of consciousness	87.54	16.29	79	11241	61999	63415703
Sopor	86.06	16.29	52	11268	22112	63455590
Antipsychotic drug level increased	83.52	16.29	29	11291	3406	63474296
Neuroleptic malignant syndrome	79.16	16.29	40	11280	12016	63465686
Electrocardiogram QT prolonged	74.71	16.29	71	11249	59459	63418243
International normalised ratio abnormal	65.59	16.29	24	11296	3280	63474422
Altered state of consciousness	65.52	16.29	46	11274	25184	63452518
Agitation	65.15	16.29	66	11254	59691	63418011
Tachycardia	64.91	16.29	92	11228	118064	63359638
Antidepressant drug level increased	63.28	16.29	14	11306	302	63477400
Suicidal ideation	62.75	16.29	66	11254	62355	63415347
Pain	62.69	16.29	27	11293	740601	62737101
Tremor	59.80	16.29	94	11226	132145	63345557
Hyperthermia	56.10	16.29	29	11291	9127	63468575
Somnolence	54.74	16.29	107	11213	178578	63299124
Drug abuse	54.64	16.29	66	11254	72452	63405250
Hypertonia	54.34	16.29	23	11297	4614	63473088
Sinus tachycardia	53.34	16.29	40	11280	24228	63453474
Myoclonus	50.93	16.29	33	11287	15835	63461867
Cerebellar syndrome	49.77	16.29	20	11300	3519	63474183
Polyuria	46.50	16.29	25	11295	8517	63469185
Akathisia	44.90	16.29	25	11295	9121	63468581
Psychomotor hyperactivity	43.93	16.29	26	11294	10637	63467065
Hypotension	43.86	16.29	127	11193	272477	63205225
Livedo reticularis	42.18	16.29	16	11304	2416	63475286
Joint swelling	41.26	16.29	5	11315	327661	63150041
Confusional state	39.83	16.29	112	11208	236268	63241434
Arthralgia	39.05	16.29	27	11293	569683	62908019
Ventricular dyskinesia	38.66	16.29	8	11312	124	63477578
Hyposmia	38.29	16.29	11	11309	696	63477006
Alopecia	38.25	16.29	7	11313	337529	63140173
Hyperchloraemia	37.46	16.29	11	11309	752	63476950
Mental disorder	36.53	16.29	33	11287	25886	63451816
Hepatocellular injury	34.98	16.29	33	11287	27348	63450354
Parkinsonism	34.22	16.29	22	11298	10417	63467285
Fatigue	34.09	16.29	67	11253	887961	62589741
Pneumonia aspiration	33.76	16.29	36	11284	34504	63443198
Poisoning	33.30	16.29	24	11296	13676	63464026
Diarrhoea	32.92	16.29	48	11272	715318	62762384
Urinary retention	32.15	16.29	33	11287	30268	63447434
Hypotonia	31.50	16.29	20	11300	9265	63468437
Mydriasis	31.50	16.29	22	11298	11934	63465768
Restlessness	31.12	16.29	32	11288	29421	63448281
Blood prolactin increased	30.17	16.29	14	11306	3489	63474213
Drug withdrawal syndrome neonatal	30.09	16.29	12	11308	2069	63475633
Muscle rigidity	29.92	16.29	21	11299	11479	63466223
Cor pulmonale acute	29.74	16.29	8	11312	397	63477305
Dialysis	29.39	16.29	20	11300	10407	63467295
Post-anoxic myoclonus	29.38	16.29	5	11315	24	63477678
Newborn persistent pulmonary hypertension	28.87	16.29	7	11313	228	63477474
Psychomotor skills impaired	28.59	16.29	12	11308	2356	63475346
Inappropriate antidiuretic hormone secretion	28.57	16.29	23	11297	15439	63462263
Heat stroke	27.93	16.29	9	11311	839	63476863
Miosis	27.88	16.29	17	11303	7336	63470366
Disturbance in attention	27.52	16.29	34	11286	38155	63439547
Urine osmolarity increased	27.09	16.29	6	11314	130	63477572
Otorrhoea	26.89	16.29	10	11310	1429	63476273
Drug level increased	26.40	16.29	26	11294	22710	63454992
Mania	26.32	16.29	20	11300	12347	63465355
Product dose omission issue	26.22	16.29	5	11315	234308	63243394
Retroplacental haematoma	25.97	16.29	6	11314	158	63477544
Psychomotor retardation	25.87	16.29	13	11307	3857	63473845
Contraindicated product administered	25.77	16.29	4	11316	217644	63260058
Shock	25.71	16.29	26	11294	23437	63454265
Hallucination, auditory	25.68	16.29	20	11300	12804	63464898
Nasopharyngitis	25.32	16.29	7	11313	254250	63223452
Circulatory collapse	25.31	16.29	25	11295	21913	63455789
Obsessive-compulsive disorder	25.28	16.29	13	11307	4047	63473655
Treatment failure	25.12	16.29	3	11317	199040	63278662
Vertigo	24.88	16.29	41	11279	59846	63417856
Cyanosis	24.73	16.29	22	11298	16913	63460789
Onychophagia	24.50	16.29	5	11315	72	63477630
Stereotypy	24.49	16.29	7	11313	435	63477267
Lactic acidosis	24.29	16.29	32	11288	38255	63439447
Arthropathy	24.26	16.29	6	11314	234786	63242916
Therapeutic product effect decreased	24.17	16.29	3	11317	193184	63284518
Postnatal growth restriction	24.10	16.29	4	11316	16	63477686
Spasmodic dysphonia	24.07	16.29	5	11315	79	63477623
Peripheral swelling	23.53	16.29	9	11311	265933	63211769
Rash	23.51	16.29	40	11280	560831	62916871
Swelling	23.26	16.29	10	11310	275368	63202334
Electrocardiogram QRS complex prolonged	23.21	16.29	14	11306	5924	63471778
Nephrogenic diabetes insipidus	22.94	16.29	8	11312	951	63476751
Hyponatraemia	22.85	16.29	57	11263	111843	63365859
Apathy	22.74	16.29	16	11304	8778	63468924
Asphyxia	22.70	16.29	14	11306	6167	63471535
Hypokalaemia	22.39	16.29	54	11266	103750	63373952
Drug hypersensitivity	22.22	16.29	14	11306	310673	63167029
Rheumatoid arthritis	21.78	16.29	9	11311	253810	63223892
Paralogism	21.75	16.29	4	11316	32	63477670
Infection	21.56	16.29	7	11313	229166	63248536
Tardive dyskinesia	20.91	16.29	15	11305	8487	63469215
Cholestasis	20.87	16.29	26	11294	29408	63448294
Foetal arrhythmia	20.30	16.29	5	11315	174	63477528
Right ventricular dilatation	20.12	16.29	8	11312	1368	63476334
Hypernatraemia	20.04	16.29	14	11306	7595	63470107
Anxiety	19.79	16.29	84	11236	217457	63260245
Drug screen false positive	19.71	16.29	7	11313	877	63476825
Abdominal discomfort	19.65	16.29	17	11303	320868	63156834
Hyperhidrosis	19.01	16.29	52	11268	107784	63369918
Loss of consciousness	18.91	16.29	55	11265	118066	63359636
Acquired haemophilia	18.66	16.29	7	11313	1024	63476678
Respiratory depression	18.42	16.29	17	11303	13698	63464004
Hyporesponsive to stimuli	18.20	16.29	7	11313	1097	63476605
Rhabdomyolysis	18.13	16.29	30	11290	43921	63433781
Morbid thoughts	18.05	16.29	6	11314	617	63477085
Completed suicide	17.98	16.29	62	11258	145611	63332091
Headache	17.78	16.29	56	11264	633185	62844517
Otitis media	17.76	16.29	11	11309	4880	63472822
Premature baby	17.47	16.29	20	11300	20715	63456987
Toxic skin eruption	17.36	16.29	16	11304	12869	63464833
Hyperprolactinaemia	17.36	16.29	10	11310	3890	63473812
Psychiatric symptom	17.10	16.29	11	11309	5212	63472490
Drug intolerance	16.98	16.29	18	11302	308643	63169059
Intestinal gangrene	16.92	16.29	3	11317	19	63477683
Junctional ectopic tachycardia	16.91	16.29	4	11316	117	63477585
Hepatic cytolysis	16.74	16.29	17	11303	15390	63462312
Generalised tonic-clonic seizure	16.50	16.29	23	11297	28993	63448709

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Antipsychotic drug level below therapeutic	352.81	20.97	89	8546	2458	34945838
Suicide attempt	351.93	20.97	178	8457	38938	34909358
Therapeutic product effect variable	346.05	20.97	87	8548	2369	34945927
Obsessive-compulsive disorder	339.27	20.97	102	8533	5462	34942834
Disinhibition	336.68	20.97	90	8545	3136	34945160
Euphoric mood	308.00	20.97	95	8540	5546	34942750
Akathisia	289.69	20.97	99	8536	8010	34940286
Increased appetite	266.54	20.97	91	8544	7338	34940958
Toxicity to various agents	154.88	20.97	217	8418	200145	34748151
Intentional overdose	127.26	20.97	97	8538	43577	34904719
Leukaemia	121.77	20.97	45	8590	4558	34943738
Therapeutic product effect incomplete	112.72	20.97	96	8539	50445	34897851
Serotonin syndrome	110.45	20.97	66	8569	19867	34928429
Dyslipidaemia	110.27	20.97	48	8587	7440	34940856
Coma	104.38	20.97	88	8547	45590	34902706
Leukopenia	104.08	20.97	101	8534	62755	34885541
Weight increased	98.56	20.97	118	8517	92915	34855381
Obesity	96.61	20.97	52	8583	12826	34935470
Prescribed overdose	94.15	20.97	48	8587	10599	34937697
Electrocardiogram QT prolonged	93.76	20.97	79	8556	40873	34907423
Neuroleptic malignant syndrome	93.21	20.97	57	8578	17877	34930419
Poisoning deliberate	92.32	20.97	43	8592	7801	34940495
Intentional self-injury	69.58	20.97	43	8592	13728	34934568
Sopor	61.58	20.97	38	8597	12098	34936198
Schizoaffective disorder	54.45	20.97	18	8617	1309	34946987
Extrapyramidal disorder	49.78	20.97	34	8601	12846	34935450
Somnolence	49.42	20.97	94	8541	111022	34837274
Agitation	48.30	20.97	65	8570	57334	34890962
Overdose	42.92	20.97	79	8556	90980	34857316
Irritability	41.40	20.97	40	8595	24650	34923646
Drug interaction	40.42	20.97	135	8500	225811	34722485
Compartment syndrome	40.08	20.97	18	8617	3000	34945296
Renal hypertension	38.99	20.97	9	8626	168	34948128
Dermatitis bullous	38.52	20.97	23	8612	6899	34941397
Loose associations	35.89	20.97	7	8628	55	34948241
Fatigue	35.69	20.97	24	8611	370629	34577667
Drug ineffective	35.12	20.97	212	8423	456539	34491757
Mania	34.15	20.97	24	8611	9487	34938809
Brachial plexus injury	34.03	20.97	7	8628	74	34948222
Hypertonia neonatal	30.33	20.97	9	8626	458	34947838
Tremor	29.68	20.97	64	8571	82523	34865773
Aggression	29.57	20.97	42	8593	38922	34909374
Hypothermia	29.34	20.97	23	8612	10725	34937571
Pneumonia	29.24	20.97	28	8607	362599	34585697
Rhabdomyolysis	28.22	20.97	56	8579	68107	34880189
Adrenergic syndrome	26.86	20.97	6	8629	96	34948200
Cough	26.61	20.97	3	8632	150137	34798159
Pain	26.13	20.97	9	8626	204666	34743630
Hyperthermia	25.40	20.97	21	8614	10556	34937740
Feelings of worthlessness	24.49	20.97	7	8628	312	34947984
Bradykinesia	24.47	20.97	14	8621	3879	34944417
Death	24.41	20.97	38	8597	398011	34550285
Suicidal ideation	24.20	20.97	39	8596	40349	34907947
Coma scale abnormal	24.09	20.97	14	8621	3994	34944302
Inappropriate antidiuretic hormone secretion	23.93	20.97	22	8613	12731	34935565
Febrile neutropenia	23.59	20.97	3	8632	136846	34811450
Dyspnoea	23.07	20.97	36	8599	376746	34571550
Arthralgia	22.53	20.97	7	8628	170034	34778262
Dyspraxia	22.32	20.97	7	8628	430	34947866
Diarrhoea	22.25	20.97	39	8596	389873	34558423
Hallucination, auditory	21.28	20.97	20	8615	11897	34936399
Cogwheel rigidity	20.98	20.97	9	8626	1343	34946953

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	342.56	16.48	228	16054	100421	79627685
Suicide attempt	309.30	16.48	199	16083	82733	79645373
Intentional overdose	306.13	16.48	217	16065	105743	79622363
Serotonin syndrome	270.25	16.48	147	16135	44880	79683226
Poisoning deliberate	220.24	16.48	97	16185	18731	79709375
Neuroleptic malignant syndrome	179.37	16.48	95	16187	27464	79700642
Drug interaction	162.81	16.48	298	15984	414885	79313221
Overdose	159.35	16.48	192	16090	184014	79544092
Toxicity to various agents	155.81	16.48	295	15987	421245	79306861
Sopor	145.04	16.48	88	16194	32922	79695184
Electrocardiogram QT prolonged	144.59	16.48	131	16151	90255	79637851
Bezoar	132.15	16.48	40	16242	2648	79725458
Intentional self-injury	118.72	16.48	77	16205	32342	79695764
Akathisia	116.44	16.48	56	16226	13203	79714903
Obsessive-compulsive disorder	101.18	16.48	40	16242	5887	79722219
Somnolence	99.08	16.48	176	16106	238805	79489301
Agitation	91.13	16.48	107	16175	99608	79628498
Antipsychotic drug level below therapeutic	85.55	16.48	24	16258	1214	79726892
Hyperthermia	84.17	16.48	50	16232	17987	79710119
Suicidal ideation	80.07	16.48	88	16194	76252	79651854
Therapeutic product effect variable	74.09	16.48	24	16258	1985	79726121
Depressed level of consciousness	72.63	16.48	94	16188	96558	79631548
Disinhibition	71.87	16.48	25	16257	2573	79725533
Tremor	71.37	16.48	126	16156	169957	79558149
Altered state of consciousness	70.96	16.48	64	16218	43758	79684348
Pain	68.69	16.48	29	16253	703773	79024333
Euphoric mood	62.93	16.48	31	16251	7695	79720411
Antidepressant drug level increased	61.46	16.48	15	16267	437	79727669
Tachycardia	61.21	16.48	121	16161	177647	79550459
Mania	61.07	16.48	41	16241	18219	79709887
Psychomotor hyperactivity	56.76	16.48	38	16244	16811	79711295
Antipsychotic drug level increased	54.86	16.48	26	16256	5931	79722175
Rhabdomyolysis	52.02	16.48	83	16199	103048	79625058
Fatigue	51.45	16.48	69	16213	929658	78798448
Arthralgia	50.47	16.48	27	16255	571776	79156330
Confusional state	50.42	16.48	161	16121	317836	79410270
Parkinsonism	50.17	16.48	35	16247	16549	79711557
International normalised ratio abnormal	49.54	16.48	24	16258	5744	79722362
Shock	45.29	16.48	50	16232	43498	79684608
Diarrhoea	44.12	16.48	70	16212	880419	78847687
Myoclonus	43.99	16.48	40	16242	27620	79700486
Hepatocellular injury	43.32	16.48	51	16231	47542	79680564
Sinus tachycardia	42.99	16.48	45	16237	36863	79691243
Extrapyramidal disorder	42.49	16.48	36	16246	22643	79705463
Inappropriate antidiuretic hormone secretion	41.74	16.48	38	16244	26275	79701831
Cerebellar syndrome	41.71	16.48	21	16261	5459	79722647
Joint swelling	41.69	16.48	5	16277	288641	79439465
Polyuria	41.52	16.48	30	16252	14984	79713122
Hallucination, auditory	41.15	16.48	34	16248	20659	79707447
Nasopharyngitis	40.36	16.48	3	16279	253878	79474228
Pneumonia aspiration	39.54	16.48	58	16224	66909	79661197
Psychomotor retardation	39.31	16.48	21	16261	6163	79721943
Renal hypertension	39.04	16.48	9	16273	204	79727902
Dyslipidaemia	38.61	16.48	26	16256	11607	79716499
Schizoaffective disorder	38.40	16.48	15	16267	2137	79725969
Muscle rigidity	38.15	16.48	32	16250	19850	79708256
Peripheral swelling	38.13	16.48	5	16277	269612	79458494
Increased appetite	37.92	16.48	26	16256	11952	79716154
Drug abuse	37.11	16.48	94	16188	162597	79565509
Loose associations	36.89	16.48	7	16275	58	79728048
Hypertonia	36.24	16.48	21	16261	7211	79720895
Prescribed overdose	35.15	16.48	41	16241	37842	79690264
Mydriasis	35.11	16.48	29	16253	17614	79710492
Compartment syndrome	34.41	16.48	18	16264	5064	79723042
Irritability	34.03	16.48	42	16240	41102	79687004
Dermatitis bullous	33.88	16.48	26	16256	14219	79713887
Apathy	33.78	16.48	25	16257	12952	79715154
Circulatory collapse	33.68	16.48	40	16242	37628	79690478
Infusion related reaction	33.21	16.48	4	16278	230233	79497873
Obesity	32.56	16.48	38	16244	35087	79693019
Brachial plexus injury	32.44	16.48	7	16275	116	79727990
Livedo reticularis	32.04	16.48	16	16266	4087	79724019
Hyperchloraemia	31.83	16.48	11	16271	1110	79726996
Hyposmia	31.75	16.48	10	16272	755	79727351
Bradykinesia	31.65	16.48	20	16262	8023	79720083
Loss of consciousness	31.23	16.48	90	16192	167853	79560253
Seizure	31.15	16.48	97	16185	188737	79539369
Mental disorder	30.93	16.48	35	16247	31267	79696839
Urinary retention	30.51	16.48	47	16235	56583	79671523
Bronchial hyperreactivity	30.25	16.48	14	16268	3026	79725080
Hyperhidrosis	29.94	16.48	83	16199	151409	79576697
Completed suicide	29.03	16.48	113	16169	245654	79482452
Abulia	28.93	16.48	10	16272	1010	79727096
Febrile neutropenia	28.85	16.48	6	16276	230993	79497113
Generalised tonic-clonic seizure	28.82	16.48	40	16242	43870	79684236
Ventricular dyskinesia	28.60	16.48	8	16274	400	79727706
Electrocardiogram QRS complex prolonged	28.49	16.48	21	16261	10812	79717294
Coma scale abnormal	27.86	16.48	19	16263	8659	79719447
Product dose omission issue	27.85	16.48	8	16274	247529	79480577
Miosis	27.42	16.48	24	16258	15765	79712341
Heat stroke	27.35	16.48	11	16271	1692	79726414
Pressure of speech	27.11	16.48	10	16272	1218	79726888
Restlessness	27.06	16.48	40	16242	46452	79681654
Blood prolactin increased	26.57	16.48	14	16268	3997	79724109
Retroplacental haematoma	26.55	16.48	6	16276	124	79727982
Hypotension	26.50	16.48	167	16115	440150	79287956
Post-anoxic myoclonus	26.29	16.48	5	16277	42	79728064
Rash	26.13	16.48	49	16233	578309	79149797
Cough	26.03	16.48	22	16260	366767	79361339
Social anxiety disorder	25.95	16.48	8	16274	563	79727543
Drug level increased	25.84	16.48	36	16246	39615	79688491
Adrenergic syndrome	25.50	16.48	6	16276	149	79727957
Breast disorder	25.22	16.48	11	16271	2070	79726036
Hypothermia	25.19	16.48	27	16255	22719	79705387
Alopecia	25.08	16.48	8	16274	231347	79496759
Speech disorder	24.97	16.48	42	16240	54403	79673703
Asphyxia	24.87	16.48	20	16262	11700	79716406
Pneumonia	24.82	16.48	62	16220	660184	79067922
Withdrawal syndrome	24.80	16.48	29	16253	26825	79701281
Abdominal pain	24.56	16.48	26	16256	389543	79338563
Poisoning	24.53	16.48	28	16254	25244	79702862
Pain in extremity	24.50	16.48	23	16259	364515	79363591
Clonus	24.42	16.48	16	16266	6824	79721282
Cor pulmonale acute	24.39	16.48	8	16274	688	79727418
Aggression	24.30	16.48	40	16242	50918	79677188
Psychiatric symptom	24.01	16.48	16	16266	7019	79721087
Intentional product misuse	23.82	16.48	57	16225	95108	79632998
Otorrhoea	23.71	16.48	10	16272	1735	79726371
Arthropathy	23.39	16.48	4	16278	177107	79550999
Therapeutic product effect decreased	23.25	16.48	3	16279	163860	79564246
Disturbance in attention	23.05	16.48	39	16243	50762	79677344
Leukopenia	22.19	16.48	63	16219	116450	79611656
Abnormal behaviour	22.15	16.48	32	16250	36389	79691717
Onychophagia	22.05	16.48	5	16277	105	79728001
Feelings of worthlessness	22.02	16.48	7	16275	545	79727561
Dyspraxia	21.73	16.48	6	16276	286	79727820
Urine osmolarity increased	21.59	16.48	6	16276	293	79727813
Anxiety	21.47	16.48	104	16178	248408	79479698
Paralogism	21.21	16.48	4	16278	32	79728074
Dialysis	20.59	16.48	22	16260	18440	79709666
Psychomotor skills impaired	20.55	16.48	13	16269	5224	79722882
Blood creatine phosphokinase increased	20.36	16.48	43	16239	66047	79662059
Pleurothotonus	20.20	16.48	10	16272	2506	79725600
Stomatitis	20.08	16.48	3	16279	146754	79581352
Contraindicated product administered	19.85	16.48	4	16278	157534	79570572
Headache	19.75	16.48	68	16214	653704	79074402
Hepatic cytolysis	19.74	16.48	26	16256	27125	79700981
Disorientation	19.52	16.48	41	16241	62735	79665371
Hypersensitivity	19.50	16.48	15	16267	262224	79465882
Morbid thoughts	19.45	16.48	7	16275	795	79727311
Swelling	19.41	16.48	10	16272	216701	79511405
Hypernatraemia	19.35	16.48	19	16263	14432	79713674
Sepsis	19.30	16.48	16	16266	269412	79458694
Hyperreflexia	19.27	16.48	15	16267	8370	79719736
Obsessive-compulsive symptom	19.18	16.48	5	16277	191	79727915
Death	19.16	16.48	56	16226	566458	79161648
Vertigo	19.06	16.48	43	16239	69039	79659067
Infection	19.05	16.48	13	16269	241699	79486407
Drug hypersensitivity	18.77	16.48	20	16262	298896	79429210
Nephrogenic diabetes insipidus	18.69	16.48	9	16273	2125	79725981
Hypokalaemia	18.45	16.48	68	16214	143972	79584134
Product use in unapproved indication	18.30	16.48	100	16182	250259	79477847
Treatment failure	18.29	16.48	6	16276	170480	79557626
Rheumatoid arthritis	18.11	16.48	10	16272	208460	79519646
Abdominal discomfort	17.82	16.48	15	16267	250712	79477394
Nausea	17.58	16.48	119	16163	957077	78771029
Depression	17.49	16.48	89	16193	216701	79511405
Spasmodic dysphonia	17.45	16.48	5	16277	273	79727833
Stupor	17.35	16.48	13	16269	6859	79721247
Drug screen false positive	17.25	16.48	7	16275	1102	79727004
Anticholinergic syndrome	16.81	16.48	10	16272	3601	79724505
Right ventricular dilatation	16.50	16.48	8	16274	1918	79726188

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AA04	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:48278	serotonergic drugs
CHEBI has role	CHEBI:48279	serotonin antagonists
CHEBI has role	CHEBI:149553	anticoronaviral drug
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D000929	Antidepressive Agents, Tricyclic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D017367	Selective Serotonin Reuptake Inhibitors
MeSH PA	D018490	Serotonin Agents
FDA EPC	N0000175752	Tricyclic Antidepressant
CHEBI has role	CHEBI:50949	SSRI
CHEBI has role	CHEBI:77402	EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Obsessive-compulsive disorder	indication	191736004	DOID:10933
Depressive disorder	off-label use	35489007
Cataplexy	off-label use	46263000
Anxiety	off-label use	48694002
Panic disorder	off-label use	371631005	DOID:594
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Glaucoma	contraindication	23986001	DOID:1686
Hyperthyroidism	contraindication	34486009	DOID:7998
Acute nephropathy	contraindication	58574008
Epilepsy	contraindication	84757009	DOID:1826
Bipolar affective disorder, current episode manic	contraindication	191618007
Disease of liver	contraindication	235856003	DOID:409
Retention of urine	contraindication	267064002
Pheochromocytoma	contraindication	302835009
Malignant hyperthermia	contraindication	405501007
Myocardial infarction in recovery phase	contraindication	418044006
Neuroblastoma	contraindication	432328008	DOID:769
Atrioventricular Conduction Defect	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Separation anxiety	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Clomicalm Tablets	Virbac AH Inc.	1
Clomipramine Hydrochloride Tablets	Mizner Bioscience LLC	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.04	Basic
pKa2	6.19	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	9.70	PDSP	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Kd	7.42	WOMBAT-PK	IUPHAR
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.28	PDSP
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.24	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.45	PDSP
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.82	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.19	PDSP
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.95	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	8.50	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.34	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	7.41	PDSP
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.01	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.70	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	7.66	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.07	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.44	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.89	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.42	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	6.32	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.69	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		IC50	5.56	CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	5.66	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.40	DRUG MATRIX
Glutathione S-transferase P	Enzyme	P09211	GSTP1_HUMAN				WOMBAT-PK
Voltage-dependent N-type calcium channel subunit alpha-1B	Ion channel	Q00975	CAC1B_HUMAN		IC50	5.05	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.71	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	6.66	PDSP
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.95	PDSP
Trypanothione reductase	Enzyme		TYTR_TRYCR		Ki	5.19	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.14	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	5.94	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	10.40	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	7.25	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter		SC6A2_MOUSE		IC50	6.05	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_MOUSE		IC50	7.15	CHEMBL
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	9.70	CHEMBL
Serotonin (5-HT) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT 5HT2B_RAT 5HT6R_RAT 5HT7R_RAT 5HT5A_RAT 5HT5B_RAT 5HT3A_RAT 5HT4R_RAT 5HT3B_RAT		IC50	8.30	CHEMBL
Serotonin 1 (5-HT1) receptor	GPCR		5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT		Ki	5.30	CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		Ki	7.29	CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT2B_RAT		Ki	8.08	CHEMBL
Trypanothione reductase	Enzyme		TYTR_TRYBB		IC50	5.47	CHEMBL
G protein-activated inward rectifier potassium channel 2	Ion channel		KCNJ6_MOUSE	BLOCKER	IC50	4.40	IUPHAR

External reference:

ID	Source
4019687	VUID
N0000147779	NUI
D00811	KEGG_DRUG
17321-77-6	SECONDARY_CAS_RN
2597	RXNORM
4019492	VANDF
4019687	VANDF
C0009010	UMLSCUI
CHEBI:47780	CHEBI
CXX	PDB_CHEM_ID
CHEMBL415	ChEMBL_ID
DB01242	DRUGBANK_ID
CHEMBL1200710	ChEMBL_ID
D002997	MESH_DESCRIPTOR_UI
2801	PUBCHEM_CID
2398	IUPHAR_LIGAND_ID
2238	INN_ID
NUV44L116D	UNII
373	MMSL
4476	MMSL
d00876	MMSL
003456	NDDF
004614	NDDF
372903001	SNOMEDCT_US
387027004	SNOMEDCT_US
96209002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3025	CAPSULE	25 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3050	CAPSULE	50 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3075	CAPSULE	75 mg	ORAL	ANDA	25 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0406-8806	CAPSULE	25 mg	ORAL	NDA	24 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0406-8807	CAPSULE	50 mg	ORAL	NDA	24 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0406-8808	CAPSULE	75 mg	ORAL	NDA	24 sections
ANAFRANIL	HUMAN PRESCRIPTION DRUG LABEL	1	0406-9906	CAPSULE	25 mg	ORAL	NDA	24 sections
ANAFRANIL	HUMAN PRESCRIPTION DRUG LABEL	1	0406-9907	CAPSULE	50 mg	ORAL	NDA	24 sections
ANAFRANIL	HUMAN PRESCRIPTION DRUG LABEL	1	0406-9908	CAPSULE	75 mg	ORAL	NDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2027	CAPSULE	25 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2037	CAPSULE	50 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0630	CAPSULE	25 mg	ORAL	ANDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0630	CAPSULE	25 mg	ORAL	ANDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0631	CAPSULE	50 mg	ORAL	ANDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0631	CAPSULE	50 mg	ORAL	ANDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0632	CAPSULE	75 mg	ORAL	ANDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0632	CAPSULE	75 mg	ORAL	ANDA	24 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7038	CAPSULE	25 mg	ORAL	ANDA	26 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7039	CAPSULE	50 mg	ORAL	ANDA	26 sections
clomiPRAMINE Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-698	CAPSULE	25 mg	ORAL	ANDA	27 sections
clomiPRAMINE Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-699	CAPSULE	50 mg	ORAL	ANDA	27 sections
clomiPRAMINE Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-700	CAPSULE	75 mg	ORAL	ANDA	27 sections
Clomipramine Hydrochloride	Human Prescription Drug Label	1	16571-683	CAPSULE	25 mg	ORAL	ANDA	23 sections
Clomipramine Hydrochloride	Human Prescription Drug Label	1	16571-684	CAPSULE	50 mg	ORAL	ANDA	23 sections
Clomipramine Hydrochloride	Human Prescription Drug Label	1	16571-685	CAPSULE	75 mg	ORAL	ANDA	23 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-849	CAPSULE	25 mg	ORAL	ANDA	21 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-849	CAPSULE	25 mg	ORAL	ANDA	21 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-850	CAPSULE	50 mg	ORAL	ANDA	21 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-850	CAPSULE	50 mg	ORAL	ANDA	21 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-851	CAPSULE	75 mg	ORAL	ANDA	21 sections